Published on August 17, 2009 at 8:32 PM
Eli Lilly and Company today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.
The Court's ruling invalidates Lilly's '826 patent, or method-of-use patent, for Gemzar((R)) (gemcitabine HCl for injection) which had been set to expire in 2013. The ruling has no bearing on Gemzar's compound patent, which remains valid until November 2010.
"We strongly disagree with the Court's ruling granting summary judgment in favor of the generic challenger," said Robert A. Armitage, senior vice president and general counsel for Lilly. "We continue to believe that our Gemzar method-of-use patent is valid and will be upheld by the courts. We intend to pursue an appeal of this decision with the Court of Appeals for the Federal Circuit. It is also important to note that today's court decision does not allow for the immediate entry of generic gemcitabine in the U.S. market. Gemzar's compound patent remains in force until November 2010."
www.Lilly.com
64edb8a3-4909-4a96-90e1-0c6d6961aea9|0|.0
Posted in: Medical Patent News
Tags: Anthracycline, Bone, Bone Marrow, Breast Cancer, Cancer, Carboplatin, Cell, Chemotherapy, Cisplatin, Constipation, Diarrhea, Gemcitabine, Gemzar, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Ovarian Cancer, Paclitaxel, Small Cell Lung Cancer